Loading stock data…
Abbott Laboratories (ABT)
$112.47+0.88 (+0.79%)
After Hours$112.00-0.47 (-0.42%)· Last close Aug 28
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abbott Laboratories in the Healthcare sector is trading at $112.47 with a market capitalization of $194.6B. Wall Street consensus targets $120.20 (25 analysts), implying a +6.9% move over the next 12 months. The stock is currently 18% below its 52-week high of $137.49, remaining 6.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +6.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $11.16B↓ | $11.46B↑ | $11.37B↑ | $11.14B |
| Gross Profit | — | $6.27B↓ | $6.54B↑ | $6.29B | $6.29B |
| Operating Income | — | $1.34B↓ | $2.25B↑ | $2.06B↑ | $2.05B |
| Net Income | — | $1.08B↓ | $1.78B↑ | $1.64B↓ | $1.78B |
Peer Comparison
JNJUNHPFE
Fundamentals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$194.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
36.40
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.21%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.64%
Volume
Today's trading volume
7.52M
Recent News
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.
Has BSX Stock Fallen Far Enough To Buy?
U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.
Dexcom, Abbott await Medicare coverage expansion for CGMs
Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.